Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Immunoglobulin Market Size to Worth around USD 28.70 Bn by 2034
The immunoglobulin market, valued at US$ 13.36 billion in 2023, is projected to reach US$ 28.70 billion by 2034, driven by its use in treating immunodeficiency and other applications. Key growth factors include immunodeficiency disorders, infections, and thrombocytopenia. North America leads with a 46% share, while Asia-Pacific is expected to grow fastest due to increased health spending and prevalence of autoimmune diseases. Recent advancements include subcutaneous injection therapies and acquisitions by major pharmaceutical companies.
Sanofi's rare disease drug finds yet another home
Sanofi sells global rights to Enjaymo to Recordati for $825M upfront, with potential $250M more if sales goals are met. Enjaymo, a treatment for cold agglutinin disease, adds to Recordati's rare disease portfolio, expected to generate €150M+ in 2025.
Alzheimer's mAb policies do not set precedent for accelerated approval, CMS's former CMO says
CMS’s former CMO, Lee Fleisher, says Alzheimer’s mAb policies won’t set precedent for accelerated approval, noting access restrictions were based on unusual circumstances. He emphasized these policies shouldn’t signal routine Medicare access limits for accelerated approvals, highlighting FDA’s broader approval labels and trial diversity issues as factors influencing CMS’s decision.
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033
The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.
Eye on Pharma: High Strength Trastuzumab Biosimilar; Originator Coverage Removals
FDA approves 420 mg strength of Hercessi (trastuzumab-strf) biosimilar; UnitedHealth to remove Humira from preferred drug lists in favor of biosimilars; Evernorth offers interchangeable ustekinumab biosimilar at no cost; Samsung Bioepis receives positive opinion for aflibercept biosimilar.
Biogen scrapped stroke drug helps patients walk independently in Phase III trial
Remedy Pharmaceuticals' CIRARA, previously scrapped by Biogen, showed 78% of patients treated with CIRARA and endovascular thrombectomy (EVT) walked independently at 12 months post-large hemispheric infarction (LHI), compared to 51% in the placebo group. Remedy plans a Phase III confirmatory trial.
Data Supports Approval of Biosimilar Aflibercept for Diabetic Macular Edema
MYL-1701P, a biosimilar for aflibercept, demonstrated clinical equivalence in the INSIGHT trial, supporting its use as an alternative for neovascular age-related macular degeneration and diabetic macular edema.
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, CRISPR Therapeutics, and Moderna are set to announce clinical trial results for next-gen weight loss drugs, cancer and autoimmune therapies, and potential new products beyond COVID-19 vaccines by year-end.
Related Clinical Trials:
Phase 3 Trial in Large Lesion Stroke Patients Demonstrates ...
Remedy Pharmaceuticals announced significant, sustained effects of CIRARA (IV glyburide) in Phase 3 CHARM trial for Large Hemispheric Infarction (LHI) patients, with odds ratios of 2.22 (p=0.03) and 6.92 (p=0.02) for lesion volumes <125 mL and EVT patients, respectively. CIRARA showed a 55% relative increase in independent walking at 12 months for EVT patients.
Red Biotechnology Market Global Trends Evaluation
The Red Biotechnology Market is projected to grow at a CAGR of 5.2% by 2031, driven by advancements in pharmaceuticals, vaccines, and diagnostics. Key players include Hoffmann-La Roche, Ltd., Merck KGaA, and Regeneron Pharmaceuticals, Inc. The market is segmented by product type, application, and end user, with regional focus on North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
© Copyright 2025. All Rights Reserved by MedPath